Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice.
Bruera G, Pepe F, Malapelle U, Di Staso M, Dal Mas A, Di Giacomo D, Scerbo G, Santilli M, Ciacco E, Simmaco M, Troncone G, Coco C, Giuliante F, Ricevuto E. Bruera G, et al. Ann Transl Med. 2021 Jun;9(12):1027. doi: 10.21037/atm-20-6636. Ann Transl Med. 2021. PMID: 34277827 Free PMC article.
General principles of chemotherapy.
Ricevuto E, Bruera G, Marchetti P. Ricevuto E, et al. Among authors: bruera g. Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):269-71. Eur Rev Med Pharmacol Sci. 2010. PMID: 20496534 Review.
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.
Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F, Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E. Bruera G, et al. BMC Cancer. 2010 Oct 19;10:567. doi: 10.1186/1471-2407-10-567. BMC Cancer. 2010. PMID: 20958992 Free PMC article. Clinical Trial.
Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy: Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52.
Bruera G, Ricevuto E. Bruera G, et al. Expert Opin Biol Ther. 2011 Jun;11(6):821-4. doi: 10.1517/14712598.2011.582462. Expert Opin Biol Ther. 2011. PMID: 21545334 Clinical Trial.
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.
Bruera G, Cannita K, Di Giacomo D, Lamy A, Troncone G, Dal Mas A, Coletti G, Frébourg T, Sabourin JC, Tosi M, Ficorella C, Ricevuto E. Bruera G, et al. BMC Med. 2012 Nov 8;10:135. doi: 10.1186/1741-7015-10-135. BMC Med. 2012. PMID: 23136868 Free PMC article.
Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.
Marampon F, Gravina GL, Popov VM, Scarsella L, Festuccia C, La Verghetta ME, Parente S, Cerasani M, Bruera G, Ficorella C, Ricevuto E, Tombolini V, Di Cesare E, Zani BM. Marampon F, et al. Among authors: bruera g. Int J Oncol. 2014 Jan;44(1):285-94. doi: 10.3892/ijo.2013.2167. Epub 2013 Nov 5. Int J Oncol. 2014. PMID: 24189697
51 results